KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer
<p><strong><span>Purpose</span></strong><span>: T<span>o identify predictive factors of nivolumab sensitivity, peripheral blood NKs and Tregs were evaluated </span>in patients with metastatic renal cancer (mRCC) enrolled in the REVOLUTION trial.</span></p> <p><strong><span>Experimental design:</span></strong><span> 57 mRCCs being treated with nivolumab, as at least second-line of therapy (REV), and 62 healthy donors (HDs) were longitudinally evaluated (</span><span>0-1-3-6-12 months</span><span>) for</span><span> peripheral NKs and Tregs, phenotype and function. </span><span>Multivariable logistic regression were conducted to identify the independent predictors. The </span><span>.632+ internal cross-validation was used to avoid overfitting. </span><span>The best cut-off value </span><span>based on three-months clinical-response</span><span> was applied to </span><span>progression-free survival (PFS)</span><span> and </span><span>overall survival (OS)</span><span>. Kaplan-Meier curves for PFS and OS were produced.</span></p> <p><strong><span>Results:</span></strong><span> </span><span>At pre-treatment, mRCCs displayed high frequency of <sup>NKp46+</sup>NKs, <sup>NKp30+</sup>NKs, <sup>KIR2DL1+</sup>NKs, <sup>KIR2DL2/DL3+</sup>NKs, and<sup> PD-1+</sup>NKs with reduced NK degranulation; as well as high frequency of Tregs, </span><sup><span>PD-1+</span></sup><span>Tregs,</span><sup><span> Helios+</span></sup><span>Tregs and </span><sup><span>ENTPD-1+</span></sup><span>Tregs</span><span>. Responder patients (R), identified as a clinical response after three-months of treatment,</span><span> presented at pre-treatment significantly low CD3<sup>+</sup>, high<sup> KIR2DL2/DL3+</sup></span><span>NKs</span><span>, high <sup>PD-1+</sup>Tregs and high <sup>Helios+</sup>Tregs. Upon multivariate analysis, only <sup>KIR2DL2/DL3</sup>NKs and <sup>Helios+</sup>Tregs held as independent predictors of nivolumab responsiveness. The <sup>KIR2DL2/DL3+</sup>NKs >35.3% identified patients with longer OS while the <sup>Helios+</sup>Tregs >34.3% displayed significantly longer PFS. After 1-month of nivolumab, R patients showed low CD3<sup>+</sup>, high NKs, <sup>KIR2DL2/DL3+</sup>NKs and <sup>ICOS+</sup>Tregs. Among these subpopulations, CD3<sup>+</sup> and <sup>KIR2DL2/DL3+</sup>NKs held as independent predictors of nivolumab efficacy. Low CD3<sup>+ </sup>(≤71%) significantly associated with longer PFS while high <sup>KIR2DL2/DL3+</sup>NKs (>23.3%) associated with both PFS and OS. </span></p> <p><strong><span>Conclusions:</span></strong><span> Pre-treatment evaluation of <sup>Helios+</sup>Tregs/<sup>KIR2DL2/DL3+</sup>NKs and one-month post-treatment CD3<sup>+</sup>/<sup> KIR2DL2/DL3+</sup>NKs will predict nivolumab response in mRCCs<span>.</span></span></p>
ShareScore
36/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 4
- Harmonization
- 4
- Access
- 16
- Reuse readiness
- 8
- Engagement
- 4
Dataset details
- Repository
- zenodo
- Published
- June 29, 2024
- License
- cc-by-4.0
- DOI
- 10.5281/zenodo.11394967
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.